Reply to Foxon, F.; Shiffman, S. Comment on "Wang et al. Consumption of JUUL vs. Other E-Cigarette Brands among U.S. E-Cigarette Users: Evidence from Wave 5 of the PATH Study.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

1 citing paper in PubMed.

1. Reply to Foxon F. & Shiffman S. Regarding Comments on "Adjei et al. 2024 Symptoms of nicotine dependence by E-cigarette and cigarette use behavior and brand: A population-based, nationally representative cross-sectional study" [Drug Alcohol Depend. 255 (2024) 111059].Drug and alcohol dependence · 2024
   Article

Corrections and comments

• Comment on
  Consumption of JUUL vs. Other E-Cigarette Brands among U.S. E-Cigarette Users: Evidence from Wave 5 of the PATH Study.2022
• Comment on
  Comment on Wang et al. Consumption of JUUL vs. Other E-Cigarette Brands among U.S. E-Cigarette Users: Evidence from Wave 5 of the PATH Study.2023

Authors and funding

9 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as